# ARC-XMOD-VERIFY-001 — Design Verification Execution Report

**Document ID:** ARC-XMOD-VERIFY-001-EXEC  
**Version:** 1.0  
**Status:** CONTROLLED — DESIGN VERIFICATION EXECUTED  
**System:** Archemedica / BAS360-WebSystem  
**Author/Document Owner:** Cassandra Harrison  
**Execution Date:** 2026-09-01  
**Design Tested:** ARC-XMOD-MODEL-001 v1.0  
**Protocol:** ARC-XMOD-VERIFY-001 v1.0

## 1. Overall Result
**NO-GO FOR PERSISTENT IMPLEMENTATION — THREE MATERIAL MODEL GAPS IDENTIFIED.**

The one-product-system / multiple-regulatory-overlay principle survives. DER, EIG, dependency coverage, reassessment, No False Closure, immutable history and tenant isolation remain usable across modalities. However, the v1.0 canonical model is not sufficiently granular to represent three important lifecycle dimensions without overloading unrelated objects.

## 2. Scenario Results
| Scenario | Result | Finding |
|---|---|---|
| XM-OQ-001 | PASS | Protocol dose change can traverse RPS → biologic/device constituents → usability/labeling/training obligations. |
| XM-OQ-002 | CONDITIONAL | Formulation change propagation works conceptually, but manufacturing/process needs first-class object rather than being hidden in a constituent. |
| XM-OQ-003 | PASS | Companion diagnostic threshold can link diagnostic constituent to eligibility/statistics/benefit-risk. |
| XM-OQ-004 | PASS | Software/cybersecurity change can link to use-related/device/clinical risk. |
| XM-OQ-005 | PASS | RCL/RSA preserve classification uncertainty without forced single-modality enum. |
| XM-OQ-006 | PASS | Classification can supersede and reopen dependencies. |
| XM-OQ-007 | PASS | Single RPS can carry jurisdiction-specific classification/applicability without duplicate product root. |
| XM-OQ-008 | CONDITIONAL | Coexisting control families are possible, but granular source-requirement-to-obligation chain is under-modeled. |
| XM-OQ-009 | FAIL | Supplier/material change requires explicit manufacturing/design/material/process controlled objects to avoid opaque free-text dependencies. |
| XM-OQ-010 | PASS | False dependency can be rejected/reclassified while preserving original edge. |
| XM-OQ-011 | PASS | Incomplete coverage blocks clean no-impact through existing DCA control. |
| XM-OQ-012 | CONDITIONAL | Source-version reopening works, but requirement granularity must be first-class to identify exactly what changed. |
| XM-OQ-013 | PASS | Canonical EVS can support multiple contextual uses without duplicate evidence. |
| XM-OQ-014 | PASS | One signal episode can causally connect device malfunction and drug-exposure/clinical safety. |
| XM-OQ-015 | PASS | Human-factors evidence can conflict with and reopen a clinical DER. |
| XM-OQ-016 | PASS | MUSE can link model version/context to product risk/evidence/DER. |
| XM-OQ-017 | PASS | Unknown applicability remains distinct from does-not-apply. |
| XM-OQ-018 | PASS | Constituent replacement can supersede without erasing historical relationships. |
| XM-OQ-019 | FAIL | Co-packaged → cross-labeled/integral topology change needs explicit Product Configuration/Presentation object; constituent identity alone is insufficient. |
| XM-OQ-020 | PASS WITH GOVERNANCE | Policy query can be constrained by ARC-POLICY-EVID-001 to neutral observation, denominator and uncertainty. |

**Count:** 15 PASS; 3 CONDITIONAL; 2 FAIL. Critical implementation gate remains closed.

## 3. Material Findings
### FINDING XMOD-001 — Product Configuration / Presentation Missing
**Severity:** Major / architecture-blocking  
**Problem:** An RPS may contain the same constituent parts in materially different configurations: integral, co-packaged, cross-labeled, reusable/non-reusable delivery system, region-specific presentation, kit, accessory relationship or versioned topology. Constituent identity does not fully describe the regulated product configuration.

**Required corrective action:** Add first-class `ProductConfiguration/Presentation (CFG-*)` with versioned topology and effective jurisdiction/lifecycle context. Changes to topology shall be controlled changes capable of triggering RSA/DER/risk/labeling/manufacturing reassessment.

### FINDING XMOD-002 — Regulatory Requirement Granularity Missing
**Severity:** Major / architecture-blocking  
**Problem:** `RSA-*` can state whether a source applies, but a source can contain many distinct requirements with different applicability, transition dates, exceptions and evidence obligations. Source-level applicability is too coarse for reliable change propagation or future policy analysis.

**Required corrective action:** Add first-class `Controlled Requirement (REQ-*)` between regulatory/standards source and RSA/OBL. Preserve requirement text locator/identifier, version/effective interval, obligation type, exceptions/conditions, interpretation provenance and supersession.

### FINDING XMOD-003 — Manufacturing / Design / Process Context Under-Modeled
**Severity:** Major / architecture-blocking  
**Problem:** Treating a manufacturing/process element as a constituent part conflates what the product *is* with how it is designed, manufactured, tested or controlled. Supplier/material/process/design changes require first-class lifecycle objects.

**Required corrective action:** Add `LifecycleControlObject (LCO-*)` with typed subdomains such as manufacturing process, material/specification, design input/output, verification/validation evidence, usability control, software configuration, test method, control strategy and packaging/labeling control. These are versioned controlled objects linked to constituents/configurations, not constituents themselves.

## 4. Policy/Standards Consequence
The findings matter beyond product implementation. Without CFG/REQ/LCO granularity, Archemedica could later produce misleading policy evidence because it would not distinguish whether burden arose from a regulation, a particular requirement, a product configuration, a manufacturing/design dependency or sponsor implementation choice.

The corrected model must preserve that causal specificity before any regulatory-science or policy analysis is considered trustworthy.

## 5. Strongest NO-BUILD Reassessment
The strongest NO-BUILD remains credible: a cross-modality ontology can become a manually maintained meta-QMS. The corrective objects therefore must be integration-friendly and sparse-by-default. Archemedica shall not require complete modeling of every requirement/process/artifact before producing value. Only objects material to a decision, dependency, risk, obligation, applicability determination or reconstruction need enter the controlled graph.

## 6. Corrective Action / Retest Plan
1. Supersede ARC-XMOD-MODEL-001 v1.0 with v1.1 adding CFG, REQ and LCO.
2. Update requirements traceability if new implementation requirements are introduced.
3. Retest XM-OQ-002, 008, 009, 012 and 019 first.
4. Regression-test remaining 15 scenarios to ensure added granularity does not create duplicate ontology/silo burden.
5. Re-run anti-bureaucracy comparison.
6. Persistent implementation remains unauthorized until all critical scenarios pass or have formally accepted residual risk.

## 7. Disposition
**NO-GO — CORRECT MODEL AND RETEST.**

This is a successful verification outcome in the quality sense: the design review identified material defects before persistence code was built. Failures are preserved and shall not be rewritten as if v1.0 passed.

## 8. Change History
| Version | Date | Change | Status |
|---|---|---|---|
| 1.0 | 2026-09-01 | Executed 20-scenario design verification; identified three architecture-blocking model gaps | CONTROLLED — NO-GO |

**END OF CONTROLLED REPORT**